Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care

H. H. Hirsch, H. Drechsler, A. Holbro, F. Hamy, P. Sendi, K. Petrovic, T. Klimkait, M. Battegay

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Data on genotypic and phenotypic resistance testing of HIV-1 in the routine clinical setting are lacking. In a retrospective single-center study, all patients (n=102) for whom genotypic resistance typing (GRT) and phenotypic resistance typing (PRT) were performed during the calendar year 2002 were examined. GRT and PRT results were concordant for 79% of the drugs, being highest for nevirapine (92%) and lowest for didanosine (57%). Concordance of results for protease inhibitors was lowest for lopinavir (78%) and highest for indinavir (88%). Discordant results for lamivudine were observed in 16% of patients; 90% of these results corresponded to high-level resistance by PRT and susceptibility by GRT. Overall, HIV loads were lower and CD4+ cell counts higher after therapy following resistance testing, but a significant association with the number of active drugs as predicted by GRT or PRT could not be identified. In a subgroup of 43 patients with virological failure under antiretroviral therapy and sufficient follow-up data, HIV loads were significantly lower after 3 and 6 months. More patients with HIV loads <400/ml had 2 or more active drugs according to PRT (21/29 [75%]) than according to GRT (15/29 [52%]; p=0.109). This was also found for HIV loads <50/ml (PRT 16/22 [72%], GRT 10/22 [42%]; p=0.103), although the differences were not statistically significant. There was no discernable difference between GRT and PRT in the clinic-based population, but the numbers of resistance tests performed are not sufficient to draw definitive conclusions.

Original languageEnglish (US)
Pages (from-to)733-738
Number of pages6
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume24
Issue number11
DOIs
StatePublished - Nov 2005

Fingerprint

HIV-1
HIV
Pharmaceutical Preparations
Lopinavir
Indinavir
Didanosine
Nevirapine
Lamivudine
CD4 Lymphocyte Count
Protease Inhibitors
Therapeutics
Population

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Cite this

Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care. / Hirsch, H. H.; Drechsler, H.; Holbro, A.; Hamy, F.; Sendi, P.; Petrovic, K.; Klimkait, T.; Battegay, M.

In: European Journal of Clinical Microbiology and Infectious Diseases, Vol. 24, No. 11, 11.2005, p. 733-738.

Research output: Contribution to journalArticle

Hirsch, H. H. ; Drechsler, H. ; Holbro, A. ; Hamy, F. ; Sendi, P. ; Petrovic, K. ; Klimkait, T. ; Battegay, M. / Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care. In: European Journal of Clinical Microbiology and Infectious Diseases. 2005 ; Vol. 24, No. 11. pp. 733-738.
@article{eeec8040fb884c829994570d70dd0b38,
title = "Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care",
abstract = "Data on genotypic and phenotypic resistance testing of HIV-1 in the routine clinical setting are lacking. In a retrospective single-center study, all patients (n=102) for whom genotypic resistance typing (GRT) and phenotypic resistance typing (PRT) were performed during the calendar year 2002 were examined. GRT and PRT results were concordant for 79{\%} of the drugs, being highest for nevirapine (92{\%}) and lowest for didanosine (57{\%}). Concordance of results for protease inhibitors was lowest for lopinavir (78{\%}) and highest for indinavir (88{\%}). Discordant results for lamivudine were observed in 16{\%} of patients; 90{\%} of these results corresponded to high-level resistance by PRT and susceptibility by GRT. Overall, HIV loads were lower and CD4+ cell counts higher after therapy following resistance testing, but a significant association with the number of active drugs as predicted by GRT or PRT could not be identified. In a subgroup of 43 patients with virological failure under antiretroviral therapy and sufficient follow-up data, HIV loads were significantly lower after 3 and 6 months. More patients with HIV loads <400/ml had 2 or more active drugs according to PRT (21/29 [75{\%}]) than according to GRT (15/29 [52{\%}]; p=0.109). This was also found for HIV loads <50/ml (PRT 16/22 [72{\%}], GRT 10/22 [42{\%}]; p=0.103), although the differences were not statistically significant. There was no discernable difference between GRT and PRT in the clinic-based population, but the numbers of resistance tests performed are not sufficient to draw definitive conclusions.",
author = "Hirsch, {H. H.} and H. Drechsler and A. Holbro and F. Hamy and P. Sendi and K. Petrovic and T. Klimkait and M. Battegay",
year = "2005",
month = "11",
doi = "10.1007/s10096-005-0044-4",
language = "English (US)",
volume = "24",
pages = "733--738",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care

AU - Hirsch, H. H.

AU - Drechsler, H.

AU - Holbro, A.

AU - Hamy, F.

AU - Sendi, P.

AU - Petrovic, K.

AU - Klimkait, T.

AU - Battegay, M.

PY - 2005/11

Y1 - 2005/11

N2 - Data on genotypic and phenotypic resistance testing of HIV-1 in the routine clinical setting are lacking. In a retrospective single-center study, all patients (n=102) for whom genotypic resistance typing (GRT) and phenotypic resistance typing (PRT) were performed during the calendar year 2002 were examined. GRT and PRT results were concordant for 79% of the drugs, being highest for nevirapine (92%) and lowest for didanosine (57%). Concordance of results for protease inhibitors was lowest for lopinavir (78%) and highest for indinavir (88%). Discordant results for lamivudine were observed in 16% of patients; 90% of these results corresponded to high-level resistance by PRT and susceptibility by GRT. Overall, HIV loads were lower and CD4+ cell counts higher after therapy following resistance testing, but a significant association with the number of active drugs as predicted by GRT or PRT could not be identified. In a subgroup of 43 patients with virological failure under antiretroviral therapy and sufficient follow-up data, HIV loads were significantly lower after 3 and 6 months. More patients with HIV loads <400/ml had 2 or more active drugs according to PRT (21/29 [75%]) than according to GRT (15/29 [52%]; p=0.109). This was also found for HIV loads <50/ml (PRT 16/22 [72%], GRT 10/22 [42%]; p=0.103), although the differences were not statistically significant. There was no discernable difference between GRT and PRT in the clinic-based population, but the numbers of resistance tests performed are not sufficient to draw definitive conclusions.

AB - Data on genotypic and phenotypic resistance testing of HIV-1 in the routine clinical setting are lacking. In a retrospective single-center study, all patients (n=102) for whom genotypic resistance typing (GRT) and phenotypic resistance typing (PRT) were performed during the calendar year 2002 were examined. GRT and PRT results were concordant for 79% of the drugs, being highest for nevirapine (92%) and lowest for didanosine (57%). Concordance of results for protease inhibitors was lowest for lopinavir (78%) and highest for indinavir (88%). Discordant results for lamivudine were observed in 16% of patients; 90% of these results corresponded to high-level resistance by PRT and susceptibility by GRT. Overall, HIV loads were lower and CD4+ cell counts higher after therapy following resistance testing, but a significant association with the number of active drugs as predicted by GRT or PRT could not be identified. In a subgroup of 43 patients with virological failure under antiretroviral therapy and sufficient follow-up data, HIV loads were significantly lower after 3 and 6 months. More patients with HIV loads <400/ml had 2 or more active drugs according to PRT (21/29 [75%]) than according to GRT (15/29 [52%]; p=0.109). This was also found for HIV loads <50/ml (PRT 16/22 [72%], GRT 10/22 [42%]; p=0.103), although the differences were not statistically significant. There was no discernable difference between GRT and PRT in the clinic-based population, but the numbers of resistance tests performed are not sufficient to draw definitive conclusions.

UR - http://www.scopus.com/inward/record.url?scp=28644444784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28644444784&partnerID=8YFLogxK

U2 - 10.1007/s10096-005-0044-4

DO - 10.1007/s10096-005-0044-4

M3 - Article

C2 - 16328557

AN - SCOPUS:28644444784

VL - 24

SP - 733

EP - 738

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 11

ER -